Syndax Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Syndax Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 108,636,000 | 153,993,000 | 154,083,000 | 133,019,000 | 105,396,000 | 114,615,000 | 295,394,000 | 94,550,000 | 97,275,000 | 57,517,000 | 74,356,000 | 71,377,000 | 120,239,000 | 188,773,000 | 221,965,000 | 71,433,000 | 68,041,000 | 64,386,000 | 115,243,000 | 56,356,000 | 53,611,000 | 44,629,000 | 24,609,000 | 30,581,000 | 26,666,000 | 58,116,000 | 33,769,000 | 26,705,000 | 32,204,000 | 27,981,000 | 35,168,000 | 20,732,000 | 22,988,000 | 22,356,000 | 23,844,000 | 12,753,000 | 14,441,000 | 23,187,000 |
| short-term investments | 346,597,000 | 358,204,000 | 418,801,000 | 256,588,000 | 319,701,000 | 319,963,000 | 275,304,000 | 269,006,000 | 301,526,000 | 374,876,000 | 401,446,000 | 266,461,000 | 246,552,000 | 209,157,000 | 217,971,000 | 158,281,000 | 185,091,000 | 206,949,000 | 177,822,000 | 113,803,000 | 133,142,000 | 54,376,000 | 35,166,000 | 41,657,000 | 53,854,000 | 34,626,000 | 47,142,000 | 62,894,000 | 66,181,000 | 85,242,000 | 94,806,000 | 99,862,000 | 106,967,000 | 70,429,000 | 81,486,000 | 102,814,000 | 111,016,000 | 110,483,000 |
| accounts receivable | 19,454,000 | 15,722,000 | 7,602,000 | |||||||||||||||||||||||||||||||||||
| inventory | 17,696,000 | 4,664,000 | 366,000 | |||||||||||||||||||||||||||||||||||
| short-term deposits | 13,473,000 | 4,116,000 | 10,029,000 | 16,788,000 | 7,170,000 | 8,583,000 | 6,885,000 | 10,265,000 | 7,223,000 | 5,812,000 | 8,595,000 | 12,870,000 | 9,887,000 | 12,979,000 | ||||||||||||||||||||||||
| other receivable | 3,629,000 | 3,590,000 | 3,507,000 | 9,582,000 | 6,073,000 | |||||||||||||||||||||||||||||||||
| collaboration receivable | 12,316,000 | 3,407,000 | 1,393,000 | 3,474,000 | 4,539,000 | 13,102,000 | ||||||||||||||||||||||||||||||||
| prepaid expenses and other current assets | 9,875,000 | 8,462,000 | 8,541,000 | 4,907,000 | 4,207,000 | 4,665,000 | 3,293,000 | 3,746,000 | 3,056,000 | 1,913,000 | 1,915,000 | 2,269,000 | 2,392,000 | 9,032,000 | 8,345,000 | 8,423,000 | 9,308,000 | 7,612,000 | 5,684,000 | 7,158,000 | 4,939,000 | 5,086,000 | 2,556,000 | 2,511,000 | 5,154,000 | 4,790,000 | 2,334,000 | 6,146,000 | 6,210,000 | 5,983,000 | 3,362,000 | 3,277,000 | 4,111,000 | 4,170,000 | 3,029,000 | 1,546,000 | 1,868,000 | 2,045,000 |
| total current assets | 531,676,000 | 548,751,000 | 603,057,000 | 414,809,000 | 446,056,000 | 453,899,000 | 580,876,000 | 380,974,000 | 409,080,000 | 441,511,000 | 489,786,000 | 357,631,000 | 392,287,000 | 420,056,000 | 448,396,000 | 238,252,000 | 262,555,000 | 278,947,000 | 298,864,000 | 177,432,000 | 191,807,000 | 104,206,000 | 62,331,000 | 74,850,000 | 85,775,000 | 97,633,000 | 83,346,000 | 95,846,000 | 104,696,000 | 119,306,000 | 133,442,000 | 123,971,000 | 134,167,000 | 97,057,000 | 108,510,000 | 117,267,000 | 127,379,000 | 135,767,000 |
| long-term investments | 62,627,000 | 89,938,000 | 119,520,000 | 10,029,000 | 29,516,000 | 87,416,000 | 29,829,000 | 15,705,000 | 19,483,000 | 16,561,000 | 5,469,000 | 12,125,000 | 3,246,000 | |||||||||||||||||||||||||
| property and equipment | 2,000 | 5,000 | 8,000 | 10,000 | 13,000 | 17,000 | 20,000 | 23,000 | 256,000 | 266,000 | 278,000 | 158,000 | 166,000 | 176,000 | 192,000 | 214,000 | 237,000 | 259,000 | 281,000 | 304,000 | 327,000 | 350,000 | 373,000 | 396,000 | 415,000 | 422,000 | 267,000 | 286,000 | 260,000 | 234,000 | 260,000 | 283,000 | 304,000 | 275,000 | ||||
| right-of-use asset | 1,629,000 | 1,801,000 | 2,022,000 | 756,000 | 1,000,000 | 1,243,000 | 1,487,000 | 1,731,000 | 1,968,000 | 929,000 | 1,039,000 | 1,152,000 | 774,000 | 873,000 | 983,000 | 1,093,000 | 338,000 | 434,000 | 290,000 | 396,000 | 502,000 | 608,000 | 716,000 | 826,000 | 1,087,000 | 1,208,000 | ||||||||||||
| restricted cash | 217,000 | 217,000 | 217,000 | 217,000 | 217,000 | 217,000 | 217,000 | 217,000 | 217,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 101,000 | 101,000 | 101,000 | 101,000 | 101,000 | 101,000 | 100,000 | 106,000 | 100,000 | 101,000 | 102,000 | 151,000 | 154,000 | 54,000 | 52,000 | |||
| total assets | 596,149,000 | 640,707,000 | 724,816,000 | 425,811,000 | 476,947,000 | 543,028,000 | 612,880,000 | 399,224,000 | 431,340,000 | 459,826,000 | 497,236,000 | 359,687,000 | 406,437,000 | 422,222,000 | 449,657,000 | 239,503,000 | 263,059,000 | 279,672,000 | 300,613,000 | 179,309,000 | 192,628,000 | 105,155,000 | 63,525,000 | 76,381,000 | 87,390,000 | 99,392,000 | 83,938,000 | 96,467,000 | 105,370,000 | 119,957,000 | 137,186,000 | 124,493,000 | 134,666,000 | 97,667,000 | 109,013,000 | 117,729,000 | 127,856,000 | 136,259,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||
| accounts payable | 17,353,000 | 10,047,000 | 11,626,000 | 4,898,000 | 11,568,000 | 8,809,000 | 9,961,000 | 6,049,000 | 10,978,000 | 8,057,000 | 4,350,000 | 7,115,000 | 6,438,000 | 8,231,000 | 5,669,000 | 5,122,000 | 3,624,000 | 6,529,000 | 3,508,000 | 3,836,000 | 1,832,000 | 8,998,000 | 6,178,000 | 6,757,000 | 2,276,000 | 4,350,000 | 1,439,000 | 3,180,000 | 5,297,000 | 2,590,000 | 2,232,000 | 2,246,000 | 3,362,000 | 2,741,000 | 2,375,000 | 2,010,000 | 1,588,000 | 2,225,000 |
| collaboration payable | 12,187,000 | 19,231,000 | 5,506,000 | 3,102,000 | 7,547,000 | 7,232,000 | 493,000 | |||||||||||||||||||||||||||||||
| royalty payable | 4,783,000 | 1,803,000 | 307,000 | |||||||||||||||||||||||||||||||||||
| accrued expenses and other current liabilities | 71,066,000 | 55,981,000 | 59,789,000 | 48,121,000 | 26,809,000 | 33,395,000 | 39,856,000 | 32,119,000 | 17,729,000 | 15,205,000 | 24,276,000 | 13,213,000 | 16,974,000 | 18,421,000 | 14,466,000 | 13,732,000 | 11,724,000 | 11,414,000 | 11,246,000 | 9,431,000 | 8,691,000 | 7,795,000 | 10,195,000 | 9,542,000 | 13,168,000 | 9,266,000 | 13,149,000 | 12,319,000 | 12,484,000 | 12,800,000 | 11,993,000 | 10,741,000 | 6,923,000 | 7,028,000 | 6,771,000 | 5,917,000 | 3,745,000 | 3,590,000 |
| current portion of royalty interest financing liability | 19,435,000 | 14,149,000 | ||||||||||||||||||||||||||||||||||||
| current portion of right-of-use liability | 344,000 | 377,000 | 471,000 | 842,000 | 981,000 | 1,042,000 | 1,035,000 | 995,000 | 957,000 | 454,000 | 434,000 | 471,000 | 299,000 | 331,000 | 361,000 | 369,000 | 397,000 | 476,000 | 316,000 | 373,000 | 427,000 | 480,000 | 478,000 | 478,000 | 530,000 | 525,000 | ||||||||||||
| current portion of capital lease | 6,000 | 7,000 | 9,000 | 10,000 | 12,000 | 12,000 | 12,000 | 11,000 | 11,000 | 5,000 | 5,000 | 4,000 | 2,000 | |||||||||||||||||||||||||
| total current liabilities | 112,987,000 | 94,551,000 | 103,549,000 | 59,377,000 | 42,472,000 | 50,805,000 | 58,096,000 | 39,174,000 | 30,168,000 | 23,721,000 | 29,065,000 | 20,803,000 | 30,925,000 | 30,551,000 | 20,683,000 | 28,712,000 | 24,292,000 | 24,568,000 | 18,872,000 | 15,157,000 | 12,467,000 | 18,790,000 | 18,368,000 | 18,294,000 | 17,491,000 | 15,658,000 | 16,105,000 | 17,016,000 | 19,298,000 | 16,907,000 | 15,798,000 | 14,207,000 | 11,505,000 | 10,989,000 | 10,366,000 | 9,147,000 | 6,553,000 | 7,035,000 |
| long-term liabilities: | ||||||||||||||||||||||||||||||||||||||
| royalty interest financing liability, less current portion | 324,413,000 | 329,644,000 | ||||||||||||||||||||||||||||||||||||
| right-of-use liability, less current portion | 1,325,000 | 1,453,000 | 1,578,000 | 133,000 | 327,000 | 578,000 | 851,000 | 1,115,000 | 588,000 | 709,000 | 768,000 | 570,000 | 643,000 | 711,000 | 798,000 | 22,000 | 60,000 | 101,000 | 172,000 | 240,000 | 306,000 | 419,000 | 525,000 | 725,000 | 830,000 | |||||||||||||
| total long-term liabilities | 325,738,000 | 331,097,000 | 333,143,000 | 2,000 | 137,000 | 334,000 | 588,000 | 864,000 | 1,131,000 | 600,000 | 722,000 | 782,000 | 13,572,000 | 17,122,000 | 20,606,000 | 11,787,000 | 24,204,000 | 26,899,000 | 29,553,000 | 32,175,000 | 32,514,000 | 32,856,000 | 13,557,000 | 14,044,000 | 14,624,000 | 15,108,000 | 14,786,000 | 15,177,000 | 15,720,000 | 16,100,000 | 17,069,000 | 13,572,000 | 13,824,000 | 14,063,000 | 14,508,000 | 14,748,000 | 15,062,000 | 15,378,000 |
| total liabilities | 438,725,000 | 425,648,000 | 436,692,000 | 59,379,000 | 42,609,000 | 51,139,000 | 58,684,000 | 40,038,000 | 31,299,000 | 24,321,000 | 29,787,000 | 21,585,000 | 44,497,000 | 47,673,000 | 41,289,000 | 40,499,000 | 48,496,000 | 51,467,000 | 48,425,000 | 47,332,000 | 44,981,000 | 51,646,000 | 31,925,000 | 32,338,000 | 32,115,000 | 30,766,000 | 30,891,000 | 32,193,000 | 35,018,000 | 33,007,000 | 32,867,000 | 27,779,000 | 25,329,000 | 25,052,000 | 24,874,000 | 23,895,000 | 21,615,000 | 22,413,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||
| common stock | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 8,000 | 8,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 |
| additional paid-in capital | 1,534,981,000 | 1,520,527,000 | 1,509,110,000 | 1,493,041,000 | 1,478,009,000 | 1,467,437,000 | 1,456,370,000 | 1,189,561,000 | 1,179,389,000 | 1,170,000,000 | 1,161,288,000 | 993,547,000 | 981,712,000 | 956,054,000 | 952,019,000 | 838,888,000 | 833,802,000 | 824,542,000 | 820,815,000 | 680,125,000 | 675,294,000 | 564,164,000 | 527,067,000 | 525,485,000 | 523,855,000 | 522,340,000 | 492,493,000 | 484,893,000 | 473,686,000 | 472,026,000 | 470,571,000 | 443,692,000 | 441,218,000 | 390,894,000 | 389,374,000 | 388,210,000 | 385,556,000 | 384,767,000 |
| accumulated other comprehensive gain | 285,000 | 527,000 | 371,000 | -817,000 | -756,000 | |||||||||||||||||||||||||||||||||
| accumulated deficit | -1,377,851,000 | -1,306,004,000 | -1,221,158,000 | -1,126,989,000 | -1,042,863,000 | -974,800,000 | -902,400,000 | -829,927,000 | -778,781,000 | -734,166,000 | -693,040,000 | -653,846,000 | -618,443,000 | -580,871,000 | -543,702,000 | -639,900,000 | -619,261,000 | -596,351,000 | -568,628,000 | -548,205,000 | -527,768,000 | -510,706,000 | -495,470,000 | -481,470,000 | -468,641,000 | -453,725,000 | -439,423,000 | -420,586,000 | -403,247,000 | -384,860,000 | -366,111,000 | -347,008,000 | -331,919,000 | -318,279,000 | -305,293,000 | -294,478,000 | -279,509,000 | -271,151,000 |
| total stockholders’ equity | 157,424,000 | 215,059,000 | 366,432,000 | 434,338,000 | 491,889,000 | 359,186,000 | 400,041,000 | 435,505,000 | 338,102,000 | 361,940,000 | 374,549,000 | 199,004,000 | 214,563,000 | 228,205,000 | 131,977,000 | 147,647,000 | 53,509,000 | 44,043,000 | 55,275,000 | 68,626,000 | 64,274,000 | 70,352,000 | 86,950,000 | 96,714,000 | 109,337,000 | 72,615,000 | 84,139,000 | 93,834,000 | 106,241,000 | 113,846,000 | ||||||||
| total liabilities and stockholders’ equity | 596,149,000 | 640,707,000 | 425,811,000 | 476,947,000 | 543,028,000 | 399,224,000 | 431,340,000 | 459,826,000 | 359,687,000 | 406,437,000 | 422,222,000 | 239,503,000 | 263,059,000 | 279,672,000 | 179,309,000 | 192,628,000 | 105,155,000 | 76,381,000 | 87,390,000 | 99,392,000 | 96,467,000 | 105,370,000 | 119,957,000 | 124,493,000 | 134,666,000 | 97,667,000 | ||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||
| other receivables | 3,635,000 | |||||||||||||||||||||||||||||||||||||
| other assets | 156,000 | 248,000 | 463,000 | 587,000 | 579,000 | 693,000 | 807,000 | 881,000 | 995,000 | 1,027,000 | 115,000 | 1,267,000 | 1,267,000 | 82,000 | 82,000 | 197,000 | 401,000 | 201,000 | 201,000 | 219,000 | 225,000 | 259,000 | 229,000 | 231,000 | 236,000 | 239,000 | 376,000 | 243,000 | 179,000 | 173,000 | 217,000 | |||||||
| liabilities and stockholders' equity | ||||||||||||||||||||||||||||||||||||||
| current portion of term loan payable | 12,116,000 | |||||||||||||||||||||||||||||||||||||
| term loan payable, less current portion | 331,565,000 | |||||||||||||||||||||||||||||||||||||
| capital lease, less current portion | 2,000 | 4,000 | 7,000 | 10,000 | 13,000 | 16,000 | 12,000 | 13,000 | 14,000 | 8,000 | ||||||||||||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive income | 163,000 | 218,000 | -806,000 | -1,605,000 | 11,000 | 17,000 | 9,000 | 53,000 | 117,000 | 48,000 | 25,000 | 58,000 | 8,000 | -143,000 | 28,000 | 36,000 | -2,000 | 56,000 | 100,000 | 192,000 | 228,000 | |||||||||||||||||
| total stockholders' equity | 288,124,000 | 554,196,000 | 467,449,000 | 408,368,000 | 252,188,000 | 31,600,000 | 53,047,000 | 104,319,000 | ||||||||||||||||||||||||||||||
| total liabilities and stockholders' equity | 724,816,000 | 612,880,000 | 497,236,000 | 449,657,000 | 300,613,000 | 63,525,000 | 83,938,000 | |||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -455,000 | -574,000 | 45,000 | -4,000 | -25,000 | -35,000 | -89,000 | -218,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive | -336,000 | |||||||||||||||||||||||||||||||||||||
| derivative liability | 187,000 | |||||||||||||||||||||||||||||||||||||
| term loan, less current portion | 12,994,000 | 16,479,000 | 19,895,000 | 10,989,000 | 13,323,000 | 17,834,000 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||
| current portion of term loan | 7,212,000 | 3,568,000 | 9,489,000 | 7,030,000 | 4,632,000 | 2,285,000 | ||||||||||||||||||||||||||||||||
| commitments | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive (income) loss | -1,335,000 | -640,000 | ||||||||||||||||||||||||||||||||||||
| commitment and contingencies | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||
| current portion of deferred revenue | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,517,000 | 1,573,000 | 1,220,000 | 1,220,000 | 1,220,000 | 1,220,000 | 1,220,000 | 1,220,000 | 1,220,000 | ||||||||||||||||
| deferred revenue, less current portion | 10,859,000 | 11,237,000 | 11,617,000 | 11,995,000 | 12,375,000 | 12,754,000 | 13,133,000 | 13,513,000 | 13,892,000 | 14,271,000 | 14,650,000 | 15,029,000 | 15,409,000 | 15,788,000 | 16,759,000 | 13,305,000 | 13,610,000 | 13,915,000 | 14,220,000 | 14,525,000 | 14,830,000 | 15,135,000 | ||||||||||||||||
| other long-term liabilities | 1,000 | 2,000 | 3,000 | 4,000 | 5,000 | 6,000 | 7,000 | 7,000 | 136,000 | 148,000 | 311,000 | 312,000 | 310,000 | 267,000 | 214,000 | 148,000 | 288,000 | 223,000 | 232,000 | 243,000 | ||||||||||||||||||
| commitments, contingencies and guarantees | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||
| loan payable | 15,602,000 | 20,006,000 | 19,896,000 | 19,792,000 | ||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2020 and december 31, 2019, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2019 and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders' equity | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at december 31, 2017 and december 31, 2016, respectively | ||||||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders' equity | 137,186,000 | |||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at september 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at june 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at march 31, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||
| common stock warrant liability | ||||||||||||||||||||||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 and 3,512,194 shares authorized; 0 and 700,435 shares issued and outstanding at december 31, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 and 0 shares authorized; 0 shares outstanding at december 31, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 109,013,000 | 117,729,000 | 127,856,000 | 136,259,000 | ||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 and 3,512,194 shares authorized; 0 and 700,435 shares issued and outstanding at september 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 and 0 shares authorized and outstanding at september 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 and 3,512,194 shares authorized; 0 and 700,435 shares issued and outstanding at june 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 and 0 shares authorized and outstanding at june 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 and 3,512,194 shares authorized; 0 and 700,435 shares issued and outstanding at march 31, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 and 0 shares authorized and outstanding at march 31, 2016 and december 31, 2015, respectively |
We provide you with 20 years of balance sheets for Syndax Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Syndax Pharmaceuticals. Explore the full financial landscape of Syndax Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Syndax Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.